Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.84B P/E - EPS this Y 54.10% Ern Qtrly Grth -
Income -84.3M Forward P/E -88.22 EPS next Y 209.00% 50D Avg Chg -3.00%
Sales 564.53M PEG -0.37 EPS past 5Y - 200D Avg Chg 11.00%
Dividend N/A Price/Book 9.28 EPS next 5Y 291.40% 52W High Chg -9.00%
Recommedations 1.90 Quick Ratio 7.22 Shares Outstanding 105.67M 52W Low Chg 45.00%
Insider Own 2.34% ROA -6.91% Shares Float 103.39M Beta 1.00
Inst Own 96.86% ROE -9.63% Shares Shorted/Prior 2.57M/2.54M Price 60.87
Gross Margin 58.83% Profit Margin -14.93% Avg. Volume 659,183 Target Price 95.84
Oper. Margin -17.18% Earnings Date Oct 31 Volume 613,113 Change -0.03%
About Intra-Cellular Therapies Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Intra-Cellular Therapies Inc. News
11/19/24 Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
11/07/24 Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
11/06/24 Intra-Cellular bolsters Caplyta data with another Phase III win
11/05/24 Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
11/02/24 Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results
11/01/24 Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
10/31/24 Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings Call Highlights: Robust Sales Growth and ...
10/30/24 ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
10/30/24 Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
10/30/24 Intra-Cellular: Q3 Earnings Snapshot
10/30/24 Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
10/23/24 Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
10/17/24 Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
10/13/24 Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
10/11/24 Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
10/10/24 JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc
09/23/24 Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
09/13/24 Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone
09/06/24 Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
09/05/24 Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now
ITCI Chatroom

User Image Aubriella_Petersen Posted - 21 hours ago

$ITCI $ROIV LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image IN0V8 Posted - 1 day ago

$ITCI UBS raises target price to $87 from $79

User Image Idvst8 Posted - 1 day ago

$ITCI - Cheap again

User Image Burningsmoke Posted - 2 days ago

$CYBN $JNJ $ITCI #premarket #stocks @Biotech_NEWS https://www.businesswire.com/news/home/20241118852918/en/Cybin-Reports-Positive-Phase-2-Data-for-CYB003-Demonstrating-Breakthrough-12-Month-Efficacy-in-Treating-Major-Depressive-Disorder

User Image juzaoftheclouds Posted - 4 days ago

$ITCI ministry of health nominee not good for the sector, not to mention the health in general

User Image sunset_PARK Posted - 5 days ago

$ITCI with both ibb and xbi index meltdown and falling below support level. I anticipate that all bios including itci will decline further in the near future, but we are aware of its intrinsic value and the position of its trend.

User Image AmyMadlung656 Posted - 5 days ago

$ITCI Competitors' agility in innovation highlights areas where KSCP can enhance its efforts to stay competitive.

User Image sunset_PARK Posted - 5 days ago

$ITCI a little bit surprised. 11.08.24. 12200, +6% w/w. Antipsychotics market+1.2%w/w. Bipolar+1%w/w. Yeah. Another record for caplyta and that y/y line below is even tilting back up after a year of flat.

User Image Gan1729 Posted - 5 days ago

$ITCI 🙋‍♂️ Guess the sBLA filing news should get this closer to triple digits

User Image CaptainStonks Posted - 6 days ago

$ITCI who’s ready for $100!!? 😍😍

User Image Doozio Posted - 1 week ago

$ITCI $ITIC INTA 🧠⏰♾️

User Image Idvst8 Posted - 1 week ago

$ITCI - Both get bought AXSM ITCI

User Image stoxx0007 Posted - 1 week ago

$ITCI = Very Solid Company right here! 👍👍 = 2 thumbs up! 😁

User Image jeffmeredith Posted - 1 week ago

$ITCI Yep, going higher

User Image sunset_PARK Posted - 1 week ago

$ITCI 11.01.24 11400, -3%w/w, antipsychotic overall market-1.2% w/w, bipolar market -1.3%.

User Image manymore Posted - 1 week ago

$itci from $9.02 to $90.52 in 5 years - fantastic company/management/Science/compounds/pipeline (Just couple of months ago it was: from $7.50 to $75 in 5 years)

User Image JanisBayerl998 Posted - 2 weeks ago

$ITCI Competitors are showing what's possible with current tech trends, and I wish KSCP would step up to that level.

User Image jeffmeredith Posted - 2 weeks ago

$ITCI $89.19 ath

User Image Benzinga Posted - 2 weeks ago

Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% $ITCI https://www.benzinga.com/general/biotech/24/11/41752158/intra-cellular-therapies-treatment-reduces-schizophrenia-relapse-risk-63

User Image Stellar_Capital Posted - 2 weeks ago

$ITCI My psychiatrist filled out all the appropriate paperwork, yet my commercial insurance has still yet to come through to cover this.

User Image manymore Posted - 2 weeks ago

$ITCI Fantastic results: On the primary endpoint, time to relapse during the double-blind treatment phase was significantly longer in patients receiving lumateperone compared to those receiving placebo (p=0.0002). There were 18 relapses (16.4%) in the lumateperone group versus 44 relapses (38.6%) in the placebo group. Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo (hazard ratio [95% CI] = 0.37, [0.22, 0.65]). Lumateperone also met the key secondary endpoint, time to all cause discontinuation during the double-blind phase (p=0.0007).

User Image Gan1729 Posted - 2 weeks ago

$ITCI Wow.. Positive Top-line from 304 PIII study for prevention of relapse /Schizophrenia https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-positive-topline-results-2

User Image Idvst8 Posted - 2 weeks ago

$AXSM ******Race to $100.00 share price****** $ITCI

User Image Darwin_Jos Posted - 2 weeks ago

$EXEL $ITCI MYNZ +10.91% PM LFG, unusually high volume activity last week, apx 30% more than average. 👇😘🚀 This stock may see the last time this price per share PT $5+ 🚀 HUGE PRs drop incoming before the Nov 13 meeting, so compliance is coming—no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead.

User Image sunset_PARK Posted - 2 weeks ago

$ITCI 10.18.24 was 11500 almost flat-1%w/w. 10.25.24 11800 +2%w/w, yeah, a new record! Antipaychotics overall market +1.4%w/w, bipolar +1.3% Curious if it can sustain this y/y 30%+ growth rate until mdd adjuby indication comes into play

User Image CaptainStonks Posted - 2 weeks ago

$ITCI how’s everyone feelin’ about hittin’ that 90 mark this month? 😍

User Image Fedtegreve Posted - 2 weeks ago

$ITCI @sunset_PARK do you happen to have the last two weeks Rx numbers by any chance, and have a great weekend all!

User Image IN0V8 Posted - 10/31/24

$ITCI Opportunity Canaccord Genuity raises PT to $119 from $113 Leerink Partners raises PT to $100 from $85 RBC raises target price to $112 from $108

User Image Sig711 Posted - 10/31/24

$ITCI Hey folks, what a great day yesterday! I sold 75% of my holdings yesterday on the assumption Sharon will do what she has done every other time the stock has spiked. While ITCI has a billion in cash, that is no where near what the organization will need to continue its growth trajectory and fund its amazing pipeline. I’m betting on another IPO, and have already placed buy orders to reflect the dilution the IPO will cause. Just my opinion!

User Image Jaydiggity Posted - 10/31/24

$ITCI I'm probably jinxing things here, but it's nice to see that there hasn't been a huge pull-back in price from yesterday's stock increase!!

Analyst Ratings
Cantor Fitzgerald Overweight Sep 20, 24
Cantor Fitzgerald Overweight Sep 16, 24
Piper Sandler Overweight Sep 6, 24
JP Morgan Overweight Aug 21, 24
RBC Capital Outperform Aug 8, 24
Cantor Fitzgerald Overweight Aug 8, 24
UBS Neutral Aug 8, 24
Goldman Sachs Neutral Aug 8, 24
Needham Buy Aug 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Halstead Michael EVP and General Coun.. EVP and General Counsel Feb 01 Sell 66.77 11,860 791,892 02/05/24
Mates Sharon Chairman, President.. Chairman, President & CEO Feb 01 Sell 67.06 33,885 2,272,328 1,050,309 02/05/24
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 01 Sell 67.08 11,860 795,569 29,700 02/05/24
Hineline Lawrence J. SVP of Finance, CFO SVP of Finance, CFO Feb 01 Sell 66.98 11,183 749,037 02/05/24
Durgam Suresh K. EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 01 Sell 67.09 6,167 413,744 5,693 02/05/24
Mates Sharon Chairman, President.. Chairman, President & CEO Jan 16 Sell 66.5 191,362 12,725,573 1,050,309 01/18/24
Mates Sharon Chairman, President.. Chairman, President & CEO Jan 16 Option 16.86 191,362 3,226,363 1,118,226 01/18/24
Halstead Michael EVP and General Coun.. EVP and General Counsel Jan 11 Sell 67.07 50,000 3,353,500 01/12/24
Halstead Michael EVP and General Coun.. EVP and General Counsel Jan 11 Option 18.34 50,000 917,000 50,000 01/12/24
Durgam Suresh K. EVP, Chief Medical O.. EVP, Chief Medical Officer Jan 02 Sell 70.99 62,282 4,421,399 01/04/24
Durgam Suresh K. EVP, Chief Medical O.. EVP, Chief Medical Officer Jan 02 Option 19.87 62,282 1,237,543 62,282 01/04/24
Durgam Suresh K. EVP, Chief Medical O.. EVP, Chief Medical Officer Dec 13 Sell 65.00 21,262 1,382,030 12/15/23
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Nov 06 Sell 55.5 42,393 2,352,812 29,700 11/08/23
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Nov 06 Option 23.94 26,754 640,491 72,093 11/08/23
Mates Sharon Chairman, President.. Chairman, President & CEO Sep 18 Sell 53.89 100,000 5,389,000 1,050,309 09/19/23
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Aug 07 Sell 58.79 55,300 3,251,087 45,339 08/09/23
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Aug 07 Option 18.59 55,300 1,028,027 100,639 08/09/23
Durgam Suresh K. EVP, Chief Medical O.. EVP, Chief Medical Officer Jul 17 Sell 65.00 1,842 119,730 21,262 07/20/23
Hineline Lawrence J. SVP of Finance CFO SVP of Finance CFO Jun 14 Sell 64.24 81,854 5,258,301 06/16/23
Hineline Lawrence J. SVP of Finance CFO SVP of Finance CFO Jun 14 Option 42.8 81,854 3,503,351 81,854 06/16/23
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 28 Sell 54.44 15,604 849,482 45,339 03/30/23
Durgam Suresh K. EVP, Chief Medical O.. EVP, Chief Medical Officer Mar 10 Sell 44.69 7,344 328,203 23,104 03/13/23
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 09 Sell 43.85 12,308 539,706 60,943 03/13/23
Halstead Michael EVP and General Coun.. EVP and General Counsel Mar 09 Sell 43.72 24,052 1,051,553 03/13/23
Hineline Lawrence J. SVP of Finance CFO SVP of Finance CFO Mar 09 Sell 43.7 21,245 928,407 03/13/23
Mates Sharon Chairman, President.. Chairman, President & CEO Mar 09 Sell 43.73 62,335 2,725,910 1,130,309 03/13/23
Mates Sharon Chairman, President.. Chairman, President & CEO Mar 09 Option 3.26 20,000 65,200 1,150,309 03/13/23
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 18 Sell 47.62 3,898 185,623 52,580 02/22/23
Durgam Suresh K. SVP, Chief Medical O.. SVP, Chief Medical Officer Feb 18 Sell 48 8,354 400,992 23,104 02/22/23
Halstead Michael EVP and General Coun.. EVP and General Counsel Feb 18 Sell 48.02 11,139 534,895 02/22/23
Hineline Lawrence J. SVP of Finance CFO SVP of Finance CFO Feb 18 Sell 48.76 64,411 3,140,680 02/22/23
Hineline Lawrence J. SVP of Finance CFO SVP of Finance CFO Feb 18 Option 12.73 53,968 687,013 53,968 02/22/23
Mates Sharon Chairman, President.. Chairman, President & CEO Feb 18 Sell 48.05 27,848 1,338,096 1,100,309 02/22/23
Mates Sharon Chairman, President.. Chairman, President & CEO Dec 13 Sell 55.00 33,083 1,819,565 1,100,309 12/15/22
Halstead Michael EVP and General Coun.. EVP and General Counsel Dec 01 Option 15.47 50,000 773,500 50,000 12/02/22
Halstead Michael EVP and General Coun.. EVP and General Counsel Dec 01 Sell 53.71 50,000 2,685,500 12/02/22
Hineline Lawrence J. SVP of Finance CFO SVP of Finance CFO Sep 21 Option 15.47 65,164 1,008,087 65,164 09/23/22
Hineline Lawrence J. SVP of Finance CFO SVP of Finance CFO Sep 21 Sell 45.64 65,164 2,974,085 09/23/22
VAN NOSTRAND ROBERT L Director Director Aug 11 Option 12.75 30,000 382,500 39,043 08/12/22
VAN NOSTRAND ROBERT L Director Director Aug 11 Sell 56.98 30,000 1,709,400 9,043 08/12/22
MARCUS JOEL S Director Director Aug 11 Sell 59.22 10,000 592,200 44,233 08/12/22
MARCUS JOEL S Director Director Jun 18 Sell 55 10,000 550,000 54,233 05/13/22
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Apr 08 Option 12.73 86,348 1,099,210 131,687 04/08/22
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Apr 08 Sell 64.37 86,348 5,558,221 45,339 04/08/22
RIGGS RORY B Director Director Mar 16 Sell 60.1 226,670 13,622,867 03/18/22
MARCUS JOEL S Director Director Mar 07 Sell 53.22 20,000 1,064,400 28,980 03/09/22
Durgam Suresh K. Chief Medical Office.. Chief Medical Officer Mar 02 Sell 56.25 8,037 452,081 23,104 03/04/22
Durgam Suresh K. Chief Medical Office.. Chief Medical Officer Feb 23 Sell 52.17 4,046 211,080 31,141 02/25/22
Neumann Mark EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 23 Sell 52.1 7,906 411,903 45,339 02/25/22
Halstead Michael EVP and General Coun.. EVP and General Counsel Feb 23 Sell 52 7,906 411,112 02/25/22